other_material
confidence high
sentiment positive
materiality 0.85
Moleculin reports positive Annamycin Phase 1B/2 results: CBR 59.4%, OS 13.5 months
Moleculin Biotech, Inc.
- Clinical benefit rate (CBR) of 59.4% (n=32): 1 partial response, 18 stable disease.
- Overall median overall survival 411 days (~13.5 months); Phase 2 median OS 13.5 months exceeds typical 2nd-line results (8–12 months).
- Overall median progression-free survival 63 days; Phase 2 at 330 mg/m2 median PFS 105 days.
- No cardiotoxicity observed across all subjects as assessed by independent expert.
- Company notes addressable STS market expected to grow to $2.6B by 2030.
item 7.01item 8.01item 9.01